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Abstract
Background: Very few data are available on treatment outcomes of adolescents living with HIV infection (whether
perinatally acquired or sexually acquired) in sub-Saharan Africa. The present study therefore compared the
treatment outcomes in adolescents with those of young adults at a public sector community-based ART
programme in Cape Town, South Africa.
Methods: Treatment outcomes of adolescents (9-19 years) were compared with those of young adults (20-28
years), enrolled in a prospective cohort between September 2002 and June 2009. Kaplan-Meier estimates and Cox
proportional hazard models were used to assess outcomes and determine associations with age, while adjusting
for potential confounders. The treatment outcomes were mortality, loss to follow-up (LTFU), immunological
response, virological suppression and virological failure.
Results: 883 patients, including 65 adolescents (47 perinatally infected and 17 sexually infected) and 818 young
adults, received ART. There was no difference in median baseline CD4 cell count between adolescents and young
adults (133.5 vs 116 cells/μL; p = 0.31). Overall mortality rates in adolescents and young adults were 1.2 (0.3-4.8)
and 3.1 (2.4-3.9) deaths per 100 person-years, respectively. Adolescents had lower rates of virological suppression (<
400 copies/mL) at 48 weeks (27.3% vs 63.1%; p < 0.001). Despite this, however, the median change in CD4 count
from baseline at 48 weeks of ART was significantly greater for adolescents than young adults (373 vs 187 cells/μL;
p = 0.0001). Treatment failure rates were 8.2 (4.6-14.4) and 5.0 (4.1-6.1) per 100 person-years in the two groups. In
multivariate analyses, there was no significant difference in LTFU and mortality between age groups but increased
risk in virological failure [AHR 2.06 (95% CI 1.11-3.81; p = 0.002)] in adolescents.
Conclusions: Despite lower virological suppression rates and higher rates of virological failure, immunological
responses were nevertheless greater in adolescents than young adults whereas rates of mortality and LTFU were
similar. Further studies to determine the reasons for poorer virological outcomes are needed.
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Background
As the HIV epidemic matures, survival of children with
perinatally acquired HIV infection into adolescence is
increasingly being documented in sub-Saharan African
countries [1,2]. In addition, the burden of HIV in the
adolescent patient population in the region is also due
to sexual transmission, with adolescents and young
adults being particularly vulnerable to this mode of
infection [3]. HIV care and treatment services in the
region need to adapt to adequately meet the specific
n e e d so ft h i se x p a n d i n gd i s e a s eb u r d e na m o n g
adolescents.
Adolescence is a complex development phase of
marked psychosocial, behavioural, physiological and cog-
nitive changes [1,4] that exacerbate the challenges of an
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structured treatment regimen. It is a time when there is
hyperawareness of physical appearance [5-7] and also a
time of experimentation, risk-taking and significant peer
influence with a need to assert an individual identity
that is distinct from caregivers [8,9]. The phase is often
associated with deviations from expected or prescribed
behaviour [9]. These factors may complicate adolescents’
transition toward taking responsibility for managing
their illness, ART adherence and clinic appointment
attendance. Adolescents have been found to have poor
adherence to antiretroviral therapy [10-12], with one
study showing a decrease in adherence as children
moved into adolescence [13]. In addition, low levels of
virological suppression [12,14-17], increased risk of viro-
logical failure [17], loss to follow-up (LTFU) [15,16] and
death have all been described [17].
These studies are almost exclusively from North
America and none have directly compared adolescents
with young adults. Sub-Saharan Africa accounts for
almost 67% of all people living with HIV/AIDS [18] and
yet only a handful of studies in the region have investi-
gated outcomes on ART in the emerging group of HIV-
infected adolescents [19-21]. We therefore sought to
determine treatment outcomes among adolescents (pre-
dominantly perinattally infected) attending a large com-
munity-based ART service in Gugulethu Township,
Cape Town, South Africa, and compared these with
young adults attending the same clinic.
Methods
Setting
The ART service described here is based in a poor peri-
urban settlement of Cape Town, South Africa. ART has
been provided for free to the participants since 2002.
Clinical and programmatic characteristics of this cohort
have been described elsewhere in detail [22-26]. In brief,
first-line ART was administered for age-specific severe
immunosuppression associated with AIDS diagnosis; or
a blood CD4 cell count < 200 cells per microliter for
adults and adolescents, according to the 2004 South
African national guidelines [27]. The first-line regimens
for all ages consisted of two nucleoside reverse tran-
scriptase inhibitors (NRTI) and a non-nucleoside reverse
transcriptase inhibitor (NNRTI). During the period of
analysis, adolescents and adults were initiated on stavu-
dine (d4T), lamivudine (3TC) and efavirenz (EFV) or
nevirapine (NVP), unless contraindicated. All CD4
count and viral load tests were performed without cost
to the patients by the Toga Laboratory “Togatainer” that
was located onsite. CD4 cell counts using flow cytome-
try (FACSCount™, Becton Dickinson, Franklin Lakes,
NJ, USA) and plasma HIV-RNA levels using the branch
DNA hybridisation technique (Versant™ HIV-1 RNA
3.0 branched chain DNA assay, Bayer HealthCare,
Leverkusen, Germany; detection range of 50-500 000
copies/mL) were measured prior to commencing ART
and then at weeks 0, 4, 8, and 16 on treatment, and
with regular 16-weekly follow-up thereafter.
Due to the escalating numbers of perinatally infected
children on ART reaching adolescence an adolescent-
centered service was introduced in April 2008 to address
the needs of this emerging group. This service inte-
grated adherence monitoring and support; peer support
groups; counselling education delivered by well trained
and sensitised staff and psychosocial support services for
adolescents and caregivers within a non-judgemental
environment.
In this study, the majority [16/19 (84.2%)] of the ado-
lescents were referred from the Red Cross War Memor-
ial Children Hospital, Cape Town, and other referral
hospitals, while the rest were from primary level or pri-
vate facilities.
Data collection
Data on clinical variables, outcomes, treatment regimens
and laboratory records were routinely collected. A
cohort study of HIV-infected adolescents and young
adults on ART between September 2002 and June 2009
was done. Treatment outcomes were censored on 30
June 2010. Ethical clearance was obtained from the
Research Ethics Committee of the University of Cape
Town. Written informed consent to have data collected
anonymously for research purposes was obtained from
all adult patient 18 years and older and caregiver con-
sent was obtained for all adolescent patients under 18
years.
Definitions
Age group
In the present study the definitions used for adolescents
(age 9-19 years) and young adults (20-28 years) were
similar to that used in the literature [19,28]. Data ana-
lysed in these two age groups were based on age at
ART initiation and patients were not switched between
age groups during follow-up.
Outcomes
LTFU referred to patients that had failed to attend the
clinic for ≥ 12 weeks and were not known to have died
or to have been transferred out to another facility.
Mortality referred to all-cause deaths notified from
any source.
Median change in CD4 counts were calculated by sub-
tracting the CD4 count measurements at each time
point after ART initiation from the baseline
measurement.
Virological suppression referred to patients achieving a
viral load < 400 copies/mL
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ally achieved virological suppression (< 400 copies/mL)
with two subsequent viral load measurements > 1000
copies/mL.
Statistical analyses
Descriptive statistics were used to characterize the demo-
graphic, clinical and laboratory variables (at baseline and/
or specific time points after ART initiation). Compari-
sons between adolescent and young adult status were
examined using chi-square tests for proportions (replaced
by Fishers exact test for sparse data), Wilcoxon rank-sum
tests and Kruskal Wallis test (for medians). Kaplan-Meier
estimates were used to describe time-to-event distribu-
tions for the following outcomes: mortality, LTFU and
virological failure. The endpoint was the time from ART
initiation to one of the following events: death, loss to
follow-up and second consecutive viral load > 1000
copies/mL. Censoring occurred at the date of death, date
of transfer to another ART facility, date of loss to follow-
up or study end (i.e. 30 June 2010), whichever occurred
first. Multivariate Cox proportional hazard models were
used to estimate hazard ratios adjusting for potential
confounders defined a prioriu s i n gt h ef o l l o w i n gv a r i -
ables: sex, baseline CD4 cell count and baseline viral
load. The proportional hazards assumption has been
checked graphically using a log-log plot and the Schoen-
feld residuals (tests and graphs). Analyses were con-
ducted among all patients (treatment-naïve and
experienced) with sub-analyses among treatment-naïve
patients where appropriate. STATA statistical software,
version 11.0 was used for analyses (STATA Corporation,
College Station, Texas, USA).
Results
Baseline characteristics
A total of 883 patients aged 9-28 years had received
ART at this service by end of June 2009. Of these, 65
were adolescents and 818 were young adults. Nineteen
(29.2%) adolescents and 103 (12.6%) young adults had
transferred into care already on ART. Adolescents had a
median age of 11.5 years [interquartile range (IQR)
10.0-17.3] with 44 (67.7%) in early (9-14 years), 8
(12.3%) in middle (15-17 years) and 13 (20.0%) in late
(18-19 years) adolescence. The majority (N = 47, 72.3%)
of adolescents had perinatally acquired HIV infection,
while 26.2% (N = 17) of them had sexually acquired
infection. A significantly higher proportion of young
adults than adolescents were female [66.2% (43/65) vs.
86.6% (708/818); p < 0.0001]. Based on this ratio and
age, our assumption is that most if not all of the young
adult population had non-perinatally acquired HIV
infection. Immunodeficiency was advanced in both ado-
lescents and young adults, as reflected by baseline CD4
cell counts (Table 1). Median baseline CD4 cell count
did not differ between adolescents and young adults
(133.5 vs 116 cells/μL; p = 0.31). The majority of adoles-
cents and young adults received NNRTI-based ART at
cohort entry [98.5% (64/65) and 98.9% (809/818),
respectively] (Table 1). There was no difference in dura-
tion of follow-up in the ART cohort in adolescents com-
pared with young adults [median 34.6 months; IQR of
17.8-48.1 vs. 31.1 months (IQR: 15.3-49.2); p = 0.59]
(results not shown here).
Programme losses (mortality and lost to follow-up)
Overall, the mortality rate was 2.9 per 100 person-years
[95% confidence interval (CI) 2.3-3.7] and the LTFU
rate was 10.0 per 100 person-years (95% CI 8.8-11.4).
Rates of mortality and LTFU disaggregated by age group
are described in Table 2. There was no significant differ-
ence in mortality and LTFU in unadjusted and adjusted
analysis (Table 2).
In a sub-analysis comparing perinatally infected ado-
lescents and young adults, there was no significant dif-
ference in mortality in unadjusted and adjusted analyses;
but, there was a significantly lower risk of LTFU in peri-
natally infected adolescents [AHR 0.39 (95% CI 0.16-
0.96; p = 0.04)] (Table 2).
Immunological and virological response
The immunological response to ART in all adolescents
was compared with that of young adults. Patients who had
transferred into care on ART were excluded in this analy-
sis since baseline CD4 counts were not known. The med-
ian change in CD4 count from baseline at the various time
points were significantly higher for all adolescents than in
young adults (Table 3). At 48 weeks, the median change
was higher for all adolescents than young adults (373 vs
187 cells/μL; p = 0.0001). When we compared perinatally
infected adolescents and young adults, a similar pattern
was observed with these adolescents having significantly
higher median changes in CD4 count (Table 3).
We then compared the virological response to ART in
adolescents to that of young adults. Patients who had
transferred in to care on ART were excluded in this
analysis since baseline HIV RNA viral loads were not
known. We found the proportion of surviving adoles-
cents achieving virological suppression (< 400 copies/
mL) was lower than young adults, and the difference
was significant after 48 weeks of ART [27.3% (9/33) vs
63.1% (270/428), p < 0.001] (Table 3). When we com-
pared perinatally infected adolescents and young adults,
a similar pattern was observed (Table 3).
Virological failure
The rate of virological failure among all patients was 5.2
(95% CI 4.3-6.3) per 100 person-years. The rate of
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8.2 (95% CI 4.6-14.4) and 5.0 (95% CI 4.1-6.1) per 100
person-years, respectively. There was a significantly
higher rate of virological failure in adolescents compared
to young adults [AHR 2.06 (95% CI 1.11-3.81; p = 0.02)]
(Figure 1). However, this association was weakened
[AHR 1.51 (95% CI 0.68-3.33); p = 0.31] in a sub-analy-
sis comparing perinatally infected adolescents and
young adults.
Discussion
In this study, adolescents were less likely to attain viro-
logical suppression and had higher rates of virological
failure compared to young adults. Despite the poorer
virological outcomes, immunological responses were
nevertheless greater in adolescents than young adults.
There was no significant difference in mortality and
LTFU rates between the two groups. In sub-analyses
comparing perinatally infected adolescents with young
adults, broadly similar results were observed with
regards to mortality, immunological and virological
response to ART. However, the association between
adolescent status and the higher rates of virological fail-
ure was weakened.
Our findings of a lower rate of virological suppression
and increased rate of virological failure in this public
health sector study are cause for concern considering
the long-term antiretroviral need these adolescents have.
These results are similar to those of a recent multi-site
study in the private health sector of Southern Africa by
Nachega et al. [19]; but differ slightly from those from
another public health sector study from a peri-urban
settlement (Khayelitsha, Cape Town) by van Cutsem et
al. [20] which observed that virological outcomes were
worse for youth (20-24 years) when compared to those
in the adolescents (10-19 years) and adults (≥ 25 years).
Virological suppression requires effective ART. This
implies the correct dose of appropriate ART being con-
sistently and correctly taken. Adolescents whilst under-
going a range of psychosocial developments are also
growing physically. Consequently, it may be important
to review the appropriateness of ART dosing as children
transition from paediatric doses into adult doses [29].
This may be particularly relevant in younger adoles-
cents. Adequate options for paediatric appropriate anti-
retroviral drugs may also play a role in the outcomes in
adolescents. Often choices are limited and formulations
are inappropriate. Adequate adherence to medication
may on the other hand, be an important factor in older
adolescents and youth where all of the psychosocial fac-
tors described here [1,4] may play a role in an indivi-
dual’s ability or willingness to be adherent. In many low
and middle income countries, where prevention of
mother-to-child transmission (PMTCT) strategies have
include monotherapy with NVP, the impact on non-
nucleoside based first-line regimens is also for
Table 1 Baseline Characteristics of HIV-infected adolescents (9-19 years) and young adults (20-28 years) at a South
African antiretroviral treatment service
Characteristics Adolescents N = 65 Young adults N = 818 p-value
Transferred-in patients, n (%) 19 (29.2) 103 (12.6)
Female, n (%) 43 (66.2) 708 (86.6) < 0.0001
CD4† (cells/μL), median (IQR) 133.5 (41-198) 116 (56-170) 0.31
Baseline viral load** (copies/ml), log10 median IQR) 4.8 (4.5-5.2) 4.8 (4.4-5.3) 0.74
ART regimen at cohort entry, n (%)
EFV-based 53 (81.5) 413 (50.5) < 0.001
NVP-based 11 (16.9) 396 (48.4)
PI-based 1 (1.5) 9 (1.1)
†Data are available for adolescents 89.2%, young adults 88.7%
**Data are available for adolescents 80.0%, young adults 81.0%
Table 2 Programme losses (mortality and lost to follow-up (LTFU) in all adolescents and perinatally infected
adolescents (9-19 years) compared with that of young adults (20-28 years)
Mortality LTFU
Age group Rates (per 100 PYS) AHR* p-value Rates (per 100 PYS) AHR* p-value
All adolescents 1.2 (0.3-4.8) 0.56 (0.13-2.32) 0.42 7.2 (4.1-12.6) 0.74 (0.41-1.34) 0.33
Perinatally infected adolescents 0.8 (0.1-5.5) 0.39 (0.05-2.86) 0.35 3.9 (1.6-9.4) 0.39 (0.16-0.96) 0.04
Young adults (ref) 3.1 (2.4-3.9) 1.00 - 10.2 (9.0-11.7) 1.00 -
PYS person-years; UHR unadjusted hazard ratio; AHR adjusted hazard ratio
*adjusted for gender, baseline CD4, baseline viral load
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particular the impact of single dose NVP on this cohort
is unlikely since the youngest adolescents described here
were born in 2001 before the clinic and provincial- and
country-wide roll-out of PMTCT [30].
Despite the poorer virological outcomes, we observed
that the median change in CD4 count from baseline was
higher for all adolescents and perinatally infected ado-
lescents than young adults, suggesting that younger and
more robust immune systems occur in adolescents. A
study conducted in the United States and Peurto Rico
conducted by Flynn et al. [16] also report improved
CD4 cell count measurements in adolescents infected
via high- risk behaviours after 3 years of follow-up in
subjects with sustained undetectable viral loads. In con-
trast, a Southern African observational cohort study
conducted by Nachega et al. [19] reported that adoles-
cents (10-19 years) were less likely to experience long-
term immune recovery than young adults (20-30 years).
These contrasting findings may be due to differences in
adolescent population between studies in terms of age
and mode of infection; our adolescent population con-
sisted of younger adolescents with predominantly peri-
natally acquired infection who had relatively better
responses to ART compared to the older adolescents
(median age, 16.4 years; 73% female) in the Nachega
cohort (presumably with sexually acquired infection on
the basis of age and sex ratio).
Our findings did not show a significant difference in
mortality and LTFU rates between the groups. Literature
on mortality and LTFU in adolescents is scant. The
absence of any statistically significant difference in mor-
tality and LTFU between adolescents and young adults
in the present study is similar to reports from a recent
study conducted in a public health sector ART cohort
from Uganda by Bakanda et al. [21]. Whilst there was
no significant difference between mortality and LTFU,
there were still some losses (death and LTFU) to the
program that need corrective interventions. Site- and
patient-related factors, such as lack of compensation
(for participants), lower caregiver education level, older
age and higher viral load, have all been associated with
increased LTFU in HIV infected children and adoles-
cents in a multi-site cohort study conducted across
Puerto Rico and the United States by Williams et al.
Table 3 Immunological and virological response to ART among all ART-naïve adolescents and perinatally infected
adolescents (9-19 years) compared with that of young adults (20-28 years)
Characteristics All ART-naïve
adolescents
N=6 4
ART-naïve young
adults
N = 715
P-
value†
ART-naïve perinatally-infected
adolescents N = 31
P-
value†
Baseline CD4 (cells/μL), median (IQR) 139 (62-198) 117 (59-170) 0.15 170 (78-228) 0.026
CD4 (cells/μL), median (IQR) change
from baseline
16 weeks 220 (133.5-314) 121 (67-199) 0.0001 188.5 (126-322) 0.0004
32 weeks 195 (136-439) 155 (97-238) 0.0008 256 (172-487) 0.0002
48 weeks 373 (255-518) 187 (118-285) 0.0001 374 (242-631) 0.0002
Virological suppression*, n(%)
16 weeks 36 (97.3) 490 (89.6) 0.13 27 (100.0) 0.077
32 weeks 12 (37.5) 331 (75.1) <
0.001
7 (28.0) <
0.001
48 weeks 9 (27.3) 270 (63.1) <
0.001
6 (24.0) <
0.001
†The p values were compared with young adults and calculated using Wilcoxon rank-sum test for continuous variables and fishers exact test for binary variables.
*The denominators at 16 weeks for all ART-naïve adolescents, perinatally infected adolescents and young adults were 37, 27 and 547 respectively; at 32 weeks
was 32, 25 and 440 respectively and at 48 weeks was 33, 25 and 427 respectively.
Figure 1 Adjusted Cox proportional hazard regression model
for virological failure among adolescents and young adults.
Virological failure was defined as 2 consecutive viral loads above
1000 copies/mL and adjustment was made for age, baseline CD4
count and viral load.
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important in these two age groups and may be quite dif-
ferent. Further research on factors associated with and
the reasons for both LTFU and mortality in adolescents
are required.
Compared to analyses using the complete group of
adolescents, sub-analyses restricted to perinatally
infected adolescents showed a weaker association
between adolescent status and higher rates of virological
failure compared to young adults. Collectively, these
data may suggest that the higher rates of virological fail-
u r ea m o n ga d o l e s c e n t sw e r em o r es t r o n g l ya s s o c i a t e d
with those with sexually acquired infection. In addition,
perinatally infected adolescents had a significantly lower
risk of LTFU, which may be attributable to the fact that
such individuals were more likely to attend the treat-
ment facility with the support of parents, family and
guardians than the older adolescents with sexually
acquired infection. This hypothesis is supported by a
recent qualitative study conducted among perinatally
infected adolescents aged 7-15 years in Cape Town that
found they viewed HIV as physically and emotionally
painful, but strong family and friend support systems
were viewed as positive aspects of their lives [4]. Thus,
differences in outcomes between the two sub-group of
adolescents may be related to a range of medical, phy-
siological, psychosocial, psychosexual and neuro-cogni-
tive issues [1,29,32].
The recent modification of services in this clinic to
include a dedicated adolescent service may or may not
be influencing adolescent outcomes since the cohort
included adolescents from before as well as after the
introduction of new adolescent services. Recommenda-
tions from other medical fields where adolescents may
have chronic illnesses requiring ongoing medication
adherence are that adolescent friendly and specific ser-
vices are more effective [33-37]. With longer follow
up, the programmatic impact of this dedicated adoles-
cent service may be assessed. This study is unusual in
that it explores treatment outcomes among all adoles-
cents, including those transferred in on treatment and
compares this to young adults. This gives insights into
the overall programmatic outcomes of the adolescent
population in this public sector ART clinic in Cape
Town, especially useful given the traffic between clinics
and within services with the realisation of greater
treatment accessibility in Southern Africa. Although
the study was conducted in a relatively large commu-
nity-based clinic, and the numbers of adolescents in
public sector ART programs in Southern Africa are
accumulating, the numbers of adolescents involved in
this cohort is still small, which is a limitation of this
study. In addition, other limitations include the lack of
data on adherence, viral resistance mutations, side-
effects to therapy, all of which will require investiga-
tion in future studies. Thed a t ap r e s e n t e dh e r ed o e s
however indicate that this group in community-based
ART programs should be evaluated separately to the
adult population, and where possible perinatally
infected adolescents and sexually infected adolescents
may have different outcomes and warrant separate eva-
luation; and similarly adolescent specific corrective
interventions should be implemented. Therefore,
further research into understanding the reasons for
LTFU, mortality, immunological and virological out-
comes in this group in whom lifelong antiviral sup-
pression is required.
Conclusions
In summary, despite lower virological suppression rates
and higher rates of virological failure, immunological
responses were nevertheless greater in adolescents than
young adults whereas rates of mortality and LTFU were
similar. Whilst this clinic has taken the steps to intro-
duce adolescent specific services, this has only been
active since 2008 and the future assessment of such ser-
vices and other interventions on mortality, LTFU,
immunological and virological outcomes in adolescents
are anticipated.
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